USC Researchers Identify Enzyme Driver of Alzheimer's Inflammation and Potential Blockers
Study Reveals Key Driver of Alzheimer's Brain Inflammation
Researchers at the University of Southern California (USC) have identified a hidden mechanism that fuels brain inflammation in Alzheimer's disease, potentially opening doors to new therapeutic approaches.
The team discovered that an enzyme called cPLA2 plays a significant role in driving the harmful inflammation associated with Alzheimer's. This is particularly notable because cPLA2 also serves important functions in normal brain activity, making targeted treatment a delicate balance.
APOE4 Gene Connection
The research is especially significant for individuals carrying the APOE4 gene, one of the strongest genetic risk factors for Alzheimer's disease. Those with this gene variant appear to be especially vulnerable to the inflammatory processes driven by cPLA2, which may help explain why the APOE4 variant confers increased disease risk.
Potential Therapeutic Compounds Identified
The USC team has identified potential drug compounds that can target and inhibit cPLA2, potentially reducing the brain inflammation that contributes to cognitive decline in Alzheimer's. While these compounds remain in the early research stage, they represent a promising new avenue for drug development.